Form 4: Bristol Myers Squibb Executive Granted 12,810 Restricted Stock Units

Bristol Myers Squibb's EVP and Chief Strategy Officer, Hiroshi Chris Shibutani, was granted 12,810 restricted stock units, vesting over three years.

Summary

• Hiroshi Chris Shibutani, Executive Vice President and Chief Strategy Officer of Bristol Myers Squibb Co. (BMY), was granted 12,810 Restricted Stock Units (RSUs).
• The transaction date for this grant was July 1, 2025.
• Each restricted stock unit converts into one share of Bristol Myers Squibb common stock upon vesting.
• The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the grant date, specifically on July 1, 2026, July 1, 2027, and July 1, 2028.
• The acquisition price for these restricted stock units was $0 per unit, which is typical for RSU grants as a form of compensation.
• Following this transaction, Hiroshi Chris Shibutani beneficially owns 12,810 restricted stock units directly.

Sentiment

Score: 7

Explanation: The document reports a standard executive compensation grant, which is a positive for aligning management incentives with shareholder interests. It does not contain any negative news or significant risks, nor does it indicate any unexpected financial performance.

Positives

• The grant of restricted stock units aligns the interests of the executive, Hiroshi Chris Shibutani, with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• This type of long-term incentive compensation is a standard practice for retaining key executive talent and motivating performance over time.

Future Outlook

The restricted stock units are scheduled to vest in three equal annual installments on July 1, 2026, July 1, 2027, and July 1, 2028, indicating a future conversion of these units into common stock.

Industry Context

The grant of restricted stock units to a senior executive is a common form of long-term incentive compensation across the pharmaceutical and broader corporate sectors. This practice is widely used to align executive interests with shareholder value creation and to ensure executive retention.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice in the pharmaceutical industry, consistent with compensation structures at major peer companies like Pfizer, Merck, and Johnson & Johnson.
• Vesting schedules over multiple years, such as the three-year annual vesting period for these RSUs, are typical for long-term incentive plans, promoting sustained performance and executive retention.
• The grant price of $0 for RSUs is standard, as these units represent a right to receive shares upon vesting, rather than a purchase.

Related Party Transactions

• Grant of 12,810 restricted stock units to Hiroshi Chris Shibutani, an executive officer, as part of his compensation package, which is a standard transaction between the company and a related party (insider).

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with shareholders, as the value of the compensation is directly tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: This grant is specific to a senior executive and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• The restricted stock units will vest in three equal annual installments on July 1, 2026, July 1, 2027, and July 1, 2028, at which point they will convert into shares of common stock.

Key Dates

Keywords

Bristol Myers Squibb, BMY, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Hiroshi Chris Shibutani, Equity Grant